Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx Trademark at the American Heart Association...more stocks inside...

Cardiol Therapeutics (NASDAQ: CRDL) presented breakthrough Phase II MAvERIC-Pilot data at the American Heart Association (AHA) Scientific Sessions 2024, showcasing CardiolRx Trademark as a potential game-changer for recurrent pericarditis treatment. The results revealed rapid pain relief within just 5 days and a dramatic reduction in pericarditis episodes, from 5.8 to 0.9 annually.

CardiolRx Trademark also shows promise in treating myocarditis, a leading cause of sudden cardiac death in younger individuals. With its non-immunosuppressive, anti-inflammatory properties, CardiolRx Trademark offers a safe and convenient oral therapy option, addressing critical gaps in care for patients at high risk of severe cardiac complications.

The compelling MAvERIC-Pilot findings pave the way for the Phase II/III MAVERIC-2 and Phase III MAVERIC-3 clinical trials, targeting broader patient populations. Cardiol is advancing its MAVERIC program while exploring CardiolRx's potential for acute myocarditis and heart failure. With orphan drug designation (ODD) secured, Cardiol Therapeutics is strategically positioned to leverage an accelerated regulatory pathway, potentially transforming treatment for rare and life-threatening heart conditions. See Entire News Article [https://can01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fcfnmedianews.com%2Fcardiol-therapeutics-advancing-orphan-drug-trial-to-phase-2-3%2F&data=05%7C02%7Cchris.firman%40cardiolrx.com%7C1715faf91dfa468709ca08dcff34a8ce%7C6f2a47bd841b4886a2a58b23821e169d%7C0%7C0%7C638665848850043412%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=5My0%2FS5P7%2BjS0e%2FtomRhfTRBgqWgGv2aH4GKgmVObeQ%3D&reserved=0]

Other Stocks to Watch:

* Biodexa Pharmaceuticals (NASDAQ: BDRX): Advancing drug delivery platforms with groundbreaking nanotechnology.
* Cerence Inc. (NASDAQ: CRNC): Revolutionizing automotive AI with cutting-edge voice and virtual assistant technology.
* Safe Pro Inc. (NASDAQ: SPAI): Innovating safety and protective solutions for diverse industries.
* Innovid Corp. (NYSE: CTV): Transforming the advertising landscape with advanced connected TV and video marketing tools.
* Peraso Inc. (NASDAQ: PRSO) received a $3.30 price target and a buy rating following its strong Q3 2024 performance, marked by 20% year-over-year operational efficiency gains and a 34% reduction in operating expenses. Read Entire Report. [https://thestreetreports.com/wp-content/uploads/2024/11/PRSO-Inter-Act-Report.pdf]

These companies, alongside Cardiol Therapeutics (NASDAQ: CRDL), are pushing the boundaries of innovation across various sectors, making them essential to watch for investors and industry enthusiasts alike.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cardiol-therapeutics-nasdaq-crdl-advances-orphan-drug-designation-for-cardiolrx-at-the-american-heart-associationmore-stocks-inside]
Country: United States
Website: http://www.thestreetreports.com



This release was published on openPR.